Literature DB >> 17984092

FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression.

Vladimir Petrovic1, Robert H Costa, Lester F Lau, Pradip Raychaudhuri, Angela L Tyner.   

Abstract

The Forkhead box M1 (FoxM1) transcription factor is essential for cell cycle progression and mitosis. FoxM1 regulates expression of Skp2 and Cks1, subunits of the SCF ubiquitin ligase complex, which ubiquitinates p27(Kip1) and targets it for degradation. Kinase-interacting stathmin (KIS) is a growth factor-dependent nuclear kinase that regulates cell cycle progression by phosphorylating p27(Kip1) to promote its nuclear export. Here we present an additional mechanism of FoxM1-mediated regulation of p27(Kip1) and provide evidence that FoxM1 regulates growth factor-induced expression of KIS. In cells harboring FoxM1 deletion or expressing FoxM1-short interfering RNA, the expression of KIS is impaired, leading to an accumulation of p27(Kip1) in the nucleus. Furthermore, we show that KIS is a direct transcriptional target of FoxM1. Thus FoxM1 promotes cell cycle progression by down-regulating p27(Kip1) through multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984092     DOI: 10.1074/jbc.M705792200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  FoxM1 mediates resistance to herceptin and paclitaxel.

Authors:  Janai R Carr; Hyun Jung Park; Zebin Wang; Megan M Kiefer; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.

Authors:  Vladimir Petrovic; Robert H Costa; Lester F Lau; Pradip Raychaudhuri; Angela L Tyner
Journal:  Cancer Biol Ther       Date:  2010-06-06       Impact factor: 4.742

3.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

4.  Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.

Authors:  Dongwei Zhang; Ana M Tari; Ugur Akar; Banu K Arun; Tiffany A LaFortune; Rene Nieves-Alicea; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2010-11-02       Impact factor: 6.261

5.  Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.

Authors:  Vaibhav Chand; Akshay Pandey; Dragana Kopanja; Grace Guzman; Pradip Raychaudhuri
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

6.  Characterization of an apparently novel β-cell line-enriched 80-88 kDa transcriptional activator of the MafA and Pdx1 genes.

Authors:  Chad S Hunter; Roland Stein
Journal:  J Biol Chem       Date:  2012-12-26       Impact factor: 5.157

7.  MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression.

Authors:  Yuwen Song; Luyan Mu; Xuezhe Han; Qingla Li; Baijing Dong; Hulun Li; Xiaoqian Liu
Journal:  J Neurooncol       Date:  2013-09-17       Impact factor: 4.130

Review 8.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

9.  Gestational diabetes mellitus resulting from impaired beta-cell compensation in the absence of FoxM1, a novel downstream effector of placental lactogen.

Authors:  Hongjie Zhang; Jia Zhang; Christine F Pope; Laura A Crawford; Rupangi C Vasavada; Shubhada M Jagasia; Maureen Gannon
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

10.  Inferring the transcriptional landscape of bovine skeletal muscle by integrating co-expression networks.

Authors:  Nicholas J Hudson; Antonio Reverter; YongHong Wang; Paul L Greenwood; Brian P Dalrymple
Journal:  PLoS One       Date:  2009-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.